Drugs / Dendritic Cell/Tumor Fusion Vaccine

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00622401 Dec 2009 → Oct 2014 breast cancer Beth Israel Deaconess Medical Center Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Dendritic Cell/Tumor Fusion Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00622401
Modality Vaccine “investigational Dendritic Cell/Tumor Fusion vaccineNCT00622401
Route Subcutaneous “injection of tumor cells fused with dendritic cells under the skin every 3 weeks” NCT00622401